Tearsheet

AstraZeneca (AZN)

Market Price (9/4/2025): $81.9 | Market Cap: $253.9 Bil
Sector: Health Care | Industry: Pharmaceuticals

AstraZeneca (AZN)

Market Price (9/4/2025): $81.9
Market Cap: $253.9 Bil
Sector: Health Care
Industry: Pharmaceuticals

Market Valuation

	9/4/25	2024	2023	2022	2021
Share Price CYE	$81.90	$64.15	$63.57	$62.67	$52.59
Market Cap CYE ($ Bil)	253.9	198.9	196.9	194.0	163.0
Total Debt ($ Bil)	32.8	30.1	28.4	29.1	30.7
Total Cash ($ Bil)	7.1	5.5	5.9	6.2	6.4
Enterprise Value ($ Bil)	279.6	229.0	225.3	223.1	193.7
Valuation Ratios
P/S TTM	4.5	3.8	4.5	4.7	4.4
P/EBIT TTM	21.7	19.6	24.6	54.8	163.4
P/E TTM	30.6	28.9	35.0	63.8	1475.0
Sector Ratios
P/S TTM (Sector)	3.8	4.1	4.5	4.5	6.7
P/EBIT TTM (Sector)	4.3	0.4	-1.9	-1.2	-0.4
P/E TTM (Sector)	-1.8	-2.2	-3.4	-2.2	-2.3

	9/4/25	2024	2023
Share Price CYE	$81.90	$64.15	$63.57
Market Cap CYE ($ Bil)	253.9	198.9	196.9
Total Debt ($ Bil)	32.8	30.1	28.4
Total Cash ($ Bil)	7.1	5.5	5.9
Enterprise Value ($ Bil)	279.6	229.0	225.3
Valuation Ratios
P/S TTM	4.5	3.8	4.5
P/EBIT TTM	21.7	19.6	24.6
P/E TTM	30.6	28.9	35.0
Sector Ratios
P/S TTM (Sector)	3.8	4.1	4.5
P/EBIT TTM (Sector)	4.3	0.4	-1.9
P/E TTM (Sector)	-1.8	-2.2	-3.4

Stock Price
Market Cap

Stock Price Chart

Return (1Y):

Market Cap Chart

Business Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. Show more AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Show less

Price Returns Compared

Expand for Detailed View

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
AZN Return	3%	20%	19%	1%	1%	28%	72%
Peers Return	7%	30%	20%	-3%	7%	-1%	70%
S&P 500 Return	16%	27%	-19%	24%	23%	10%	100%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: LLY, JNJ, MRK, PFE, BMY.
[3] 2025 data is for the year up to 9/3/2025 (YTD)

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	AstraZeneca (AZN) Valuation Ratios Comparison	Financials
2	AstraZeneca Total Shareholder Return (TSR): 3.0% in 2024 and 8.8% 3-yr compounded annual returns (above peer average)
3	Should You Buy AstraZeneca Stock?	Buy or Fear
4	AstraZeneca (AZN) Operating Cash Flow Comparison	Financials
5	AstraZeneca (AZN) Net Income Comparison	Financials
6	AstraZeneca (AZN) Operating Income Comparison	Financials
7	AstraZeneca (AZN) Revenue Comparison	Financials

	Title
0	ARTICLES
1	AstraZeneca (AZN) Valuation Ratios Comparison
2	AstraZeneca Total Shareholder Return (TSR): 3.0% in 2024 and 8.8% 3-yr compounded annual returns (above peer average)
3	Should You Buy AstraZeneca Stock?
4	AstraZeneca (AZN) Operating Cash Flow Comparison
5	AstraZeneca (AZN) Net Income Comparison
6	AstraZeneca (AZN) Operating Income Comparison
7	AstraZeneca (AZN) Revenue Comparison

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	XELA	Exela Technologies	212.4%	-95.5%
2	TKCM	Token Communities	82.8%	-64.7%
3	ANGGF	Angang Steel	61.2%	25.0%
4	BATMF	British American Tobacco Malaysia	43.4%	59.2%
5	KYSEF	Kyushu Electric Power	32.1%	32.1%
6	STTK	Shattuck Labs	26.7%	5.8%
7	KTHAF	Krung Thai Bank	24.0%	24.0%
8	SFOSF	Shanghai Fosun Pharmaceutical	23.7%	61.7%
9	INDOY	Indorama Ventures	20.9%	-5.5%
10	M	Macy's	20.7%	-1.0%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
2	MGAWF	Megaworld	-71.0%	-71.0%
3	PTTMF	PT Timah	-62.8%	-83.1%
4	PTJSF	PT Jasa Marga	-50.9%	-50.9%
5	UNLRF	PT Unilever Indonesia	-41.3%	-17.6%
6	DLNDY	D&L Industries	-37.5%	-30.7%
7	SUCEF	Sumitomo Osaka Cement	-37.4%	-37.4%
8	PTKFF	PT Kalbe Farma	-34.7%	-32.1%
9	SMTGF	SMA Solar Technology	-30.1%	28.4%
10	PMDKF	PT Mitra Adiperkasa	-28.6%	-48.9%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	EAF	GrafTech International	804.0%	-47.2%
2	RLMD	Relmada Therapeutics	122.3%	182.7%
3	XELA	Exela Technologies	109.6%	-95.5%
4	PSNYW	Polestar Automotive UK	96.2%	141.5%
5	TKCM	Token Communities	82.8%	-64.7%
6	PHJMF	PT Hanjaya Mandala Sampoerna	66.7%	34.8%
7	ANGGF	Angang Steel	61.2%	25.0%
8	DTNOF	DNO	49.5%	141.9%
9	BW	Babcock & Wilcox Enterprises	48.5%	54.9%
10	MDB	MongoDB	46.0%	34.4%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	NXTT	Next Technology	-74.5%	-89.4%
4	SCGY	Scientific Energy	-72.7%	-26.9%
5	MGAWF	Megaworld	-71.0%	-71.0%
6	TTOO	T2 Biosystems	-67.7%	-99.0%
7	PTTMF	PT Timah	-62.8%	-83.1%
8	PIGEF	Pigeon	-62.4%	-62.4%
9	NEGG	Newegg Commerce	-53.8%	290.6%
10	PTJSF	PT Jasa Marga	-50.9%	-50.9%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	MMEX	MMEX Resources	∞%	-50.0%
2	TAWNF	Thai Airways International	3674.5%	3400.0%
3	NOKPF	Nok Airlines	2400.0%	81.8%
4	AYRWF	Ayr Wellness	509.5%	-94.6%
5	XELA	Exela Technologies	379.0%	-95.5%
6	SRNE	Sorrento Therapeutics	233.3%	900.0%
7	PGEN	Precigen	169.9%	324.1%
8	TLS	Telos	154.7%	89.2%
9	SATS	EchoStar	142.7%	179.1%
10	RLMD	Relmada Therapeutics	139.0%	182.7%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	TTOO	T2 Biosystems	-94.8%	-99.0%
4	NXTT	Next Technology	-86.5%	-89.4%
5	OTRK	Ontrak	-78.2%	-96.6%
6	SCGY	Scientific Energy	-72.7%	-26.9%
7	PPCB	Propanc Biopharma	-72.1%	-79.1%
8	MGAWF	Megaworld	-71.0%	-71.0%
9	PTTMF	PT Timah	-62.8%	-83.1%
10	PIGEF	Pigeon	-62.4%	-62.4%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	XELA	Exela Technologies	212.4%	-95.5%
2	TKCM	Token Communities	82.8%	-64.7%
3	ANGGF	Angang Steel	61.2%	25.0%
4	BATMF	British American Tobacco Malaysia	43.4%	59.2%
5	KYSEF	Kyushu Electric Power	32.1%	32.1%
6	STTK	Shattuck Labs	26.7%	5.8%
7	KTHAF	Krung Thai Bank	24.0%	24.0%
8	SFOSF	Shanghai Fosun Pharmaceutical	23.7%	61.7%
9	INDOY	Indorama Ventures	20.9%	-5.5%
10	M	Macy's	20.7%	-1.0%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
2	MGAWF	Megaworld	-71.0%	-71.0%
3	PTTMF	PT Timah	-62.8%	-83.1%
4	PTJSF	PT Jasa Marga	-50.9%	-50.9%
5	UNLRF	PT Unilever Indonesia	-41.3%	-17.6%
6	DLNDY	D&L Industries	-37.5%	-30.7%
7	SUCEF	Sumitomo Osaka Cement	-37.4%	-37.4%
8	PTKFF	PT Kalbe Farma	-34.7%	-32.1%
9	SMTGF	SMA Solar Technology	-30.1%	28.4%
10	PMDKF	PT Mitra Adiperkasa	-28.6%	-48.9%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	EAF	GrafTech International	804.0%	-47.2%
2	RLMD	Relmada Therapeutics	122.3%	182.7%
3	XELA	Exela Technologies	109.6%	-95.5%
4	PSNYW	Polestar Automotive UK	96.2%	141.5%
5	TKCM	Token Communities	82.8%	-64.7%
6	PHJMF	PT Hanjaya Mandala Sampoerna	66.7%	34.8%
7	ANGGF	Angang Steel	61.2%	25.0%
8	DTNOF	DNO	49.5%	141.9%
9	BW	Babcock & Wilcox Enterprises	48.5%	54.9%
10	MDB	MongoDB	46.0%	34.4%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	NXTT	Next Technology	-74.5%	-89.4%
4	SCGY	Scientific Energy	-72.7%	-26.9%
5	MGAWF	Megaworld	-71.0%	-71.0%
6	TTOO	T2 Biosystems	-67.7%	-99.0%
7	PTTMF	PT Timah	-62.8%	-83.1%
8	PIGEF	Pigeon	-62.4%	-62.4%
9	NEGG	Newegg Commerce	-53.8%	290.6%
10	PTJSF	PT Jasa Marga	-50.9%	-50.9%

Peer Comparisons for AstraZeneca

Financials

	AZN	LLY	JNJ	MRK	PFE	BMY	Median
Name	AstraZen.	Eli Lilly	Johnson .	Merck	Pfizer	Bristol-.
Mkt Price	-	735.19	178.06	85.48	24.98	47.41	85.48
Mkt Cap	-	660.1	428.5	214.6	142.0	96.3	214.6
Rev LTM	-	53,258	90,627	63,616	63,833	47,636	63,616
Op Inc LTM	-	22,882	22,228	19,821	16,663	7,870	19,821
FCF LTM	-	-50	16,397	14,722	12,438	13,086	13,086
FCF 3Y Avg	-	-156	16,926	12,899	9,304	12,225	12,225
CFO LTM	-	10,938	23,028	18,534	15,188	14,310	15,188
CFO 3Y Avg	-	7,230	22,248	16,766	12,584	13,419	13,419

Growth & Margins

	AZN	LLY	JNJ	MRK	PFE	BMY	Median
Name	AstraZen.	Eli Lilly	Johnson .	Merck	Pfizer	Bristol-.
Rev Chg LTM	-	36.8%	4.7%	1.8%	13.5%	4.6%	4.7%
Rev Chg 3Y Avg	-	23.4%	4.0%	3.7%	-12.4%	0.5%	3.7%
Rev Chg Q	-	37.6%	5.8%	-1.9%	10.3%	-5.6%	5.8%
QoQ Delta Rev Chg LTM	-	8.7%	1.5%	-0.5%	2.2%	-1.4%	1.5%
Op Mgn LTM	-	43.0%	24.5%	31.2%	26.1%	16.5%	26.1%
Op Mgn 3Y Avg	-	35.6%	26.3%	22.6%	20.2%	17.3%	22.6%
QoQ Delta Op Mgn LTM	-	1.8%	-0.2%	-0.8%	1.8%	4.3%	1.8%
CFO/Rev LTM	-	20.5%	25.4%	29.1%	23.8%	30.0%	25.4%
CFO/Rev 3Y Avg	-	17.8%	25.7%	27.2%	18.8%	28.9%	25.7%
FCF/Rev LTM	-	-0.1%	18.1%	23.1%	19.5%	27.5%	19.5%
FCF/Rev 3Y Avg	-	0.5%	19.6%	20.9%	13.8%	26.4%	19.6%

Valuation

	AZN	LLY	JNJ	MRK	PFE	BMY	Median
Name	AstraZen.	Eli Lilly	Johnson .	Merck	Pfizer	Bristol-.
Mkt Cap	-	660.1	428.5	214.6	142.0	96.3	214.6
P/S	-	12.4	4.7	3.4	2.2	2.0	3.4
P/EBIT	-	37.1	15.2	10.5	10.6	11.9	11.9
P/E	-	47.8	18.9	13.1	13.2	17.8	17.8
P/CFO	-	60.4	18.6	11.6	9.4	6.7	11.6
Total Yield	-	2.9%	8.1%	11.4%	12.7%	10.7%	10.7%
Dividend Yield	-	0.8%	2.8%	3.7%	5.1%	5.1%	3.7%
FCF Yield 3Y Avg	-	0.1%	4.5%	5.1%	5.7%	12.4%	5.1%
D/E	-	0.1	0.1	0.2	0.4	0.5	0.2
Net D/E	-	0.1	0.1	0.1	0.3	0.4	0.1

Returns

	AZN	LLY	JNJ	MRK	PFE	BMY	Median
Name	AstraZen.	Eli Lilly	Johnson .	Merck	Pfizer	Bristol-.
1M Rtn	-	-3.3%	7.2%	7.8%	6.3%	7.2%	7.2%
3M Rtn	-	-1.9%	16.2%	11.9%	8.8%	-1.4%	8.8%
6M Rtn	-	-19.0%	9.4%	-5.9%	0.6%	-19.4%	-5.9%
12M Rtn	-	-22.8%	10.8%	-25.4%	-7.8%	-1.9%	-7.8%
3Y Rtn	-	150.2%	19.9%	8.2%	-35.6%	-22.6%	8.2%
1M Excs Rtn	-	-6.2%	4.3%	5.0%	3.5%	4.3%	4.3%
3M Excs Rtn	-	-9.5%	7.3%	5.1%	0.2%	-10.9%	0.2%
6M Excs Rtn	-	-30.3%	-1.5%	-16.2%	-11.0%	-29.6%	-16.2%
12M Excs Rtn	-	-36.7%	-2.6%	-39.5%	-21.7%	-14.9%	-21.7%
3Y Excs Rtn	-	80.5%	-36.1%	-49.4%	-91.3%	-78.5%	-49.4%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End		12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date		2/18/2025	2/20/2024	2/21/2023	2/22/2022	2/16/2021	3/3/2020
Key Financials
Total Revenue	56,501	54,073	45,811	44,351	37,417	26,617	24,384
Ebitda	16,901	15,438	13,422	9,085	5,113	8,084	6,712
Operating Income	11,324	10,251	8,722	4,512	-139	3,916	1,738
Net Income	8,295	7,035	5,955	3,288	112	3,196	1,335
EPS	2.67	2.27	1.92	1.06	0.04	1.22	0.52
Growth Rates
Total Revenue Growth	15.0%	18.0%	3.3%	18.5%	40.6%	9.2%	10.4%
EBITDA Growth	19.6%	15.0%	47.7%	77.7%	-36.8%	20.4%	-5.6%
Operating Income Growth	25.1%	17.5%	93.3%	3346.0%	-103.5%	125.3%	236.8%
Net Income Growth	28.8%	18.1%	81.1%	2835.7%	-96.5%	139.4%	-38.1%
Margins
EBITDA Margin	29.9%	28.6%	29.3%	20.5%	13.7%	30.4%	27.5%
Operating Income Margin	20.0%	19.0%	19.0%	10.2%	-0.4%	14.7%	7.1%
Net Income Margin	14.7%	13.0%	13.0%	7.4%	0.3%	12.0%	5.5%
Cash & Debt
Total Cash	7,108	5,525	5,860	6,243	6,398	7,992	6,217
Total Debt	32,839	30,114	28,407	29,143	30,688	20,380	18,227
Net Debt / (Cash)	25,731	24,589	22,547	22,900	24,290	12,388	12,010
Cash Flows
Net Cash from Operations	13,389	11,861	10,345	9,808	5,963	4,799	2,969
Free Cash from Operations	8,184	7,275	6,567	7,237	3,763	2,193	509
Returns to Shareholders
Dividends	4,936	4,629	4,481	4,364	3,856	3,572	3,592
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	7/29/2025	4/29/2025	2/6/2025	11/12/2024	7/25/2024	4/25/2024	2/6/2025	11/9/2023	7/28/2023	4/27/2023	2/21/2023	11/10/2022
Key Financials Quarterly
Total Revenue	14,457	13,588	14,891	13,565	12,938	12,679	12,024	11,492	11,416	10,879	11,207	10,982
Ebitda	4,955	5,035	2,809	4,102	4,119	4,468	2,216	3,326	3,795	4,129	2,376	2,595
Operating Income	3,508	3,674	2,036	2,106	2,746	3,115	1,234	1,954	2,456	2,308	1,910	1,245
Net Income	2,450	2,916	1,500	1,429	1,927	2,179	960	1,374	1,818	1,803	901	1,640
EPS	0.79	0.94	0.48	0.46	0.62	0.70	0.31	0.45	0.58	0.58	0.29	0.53
Key Financials TTM
Total Revenue TTM	56,501	54,982	54,073	51,206	49,133	47,611	45,811	44,994	44,484	43,839	44,350	45,154
Ebitda TTM	16,901	16,065	15,498	14,905	14,129	13,805	13,466	13,626	12,895	11,015	9,084	6,384
Operating Income TTM	11,324	10,562	10,003	9,201	9,049	8,759	7,952	8,628	7,919	6,002	4,572	1,175
Net Income TTM	8,295	7,772	7,035	6,495	6,440	6,331	5,955	5,896	6,162	4,704	3,287	2,039
Growth Rates Quarterly
Total Revenue Growth	11.7%	7.2%	23.8%	18.0%	13.3%	16.5%	7.3%	4.6%	6.0%	-4.5%	-6.7%	11.3%
EBITDA Growth	20.3%	12.7%	26.8%	23.3%	8.5%	8.2%	-6.7%	28.2%	98.2%	87.9%	833.3%	131.3%
Operating Income Growth	27.7%	17.9%	65.0%	7.8%	11.8%	35.0%	-35.4%	56.9%	355.7%	162.9%	228.4%	174.4%
Net Income Growth	27.1%	33.8%	56.2%	4.0%	6.0%	20.9%	6.5%	-16.2%	405.0%	367.1%	359.7%	199.3%
Margins Quarterly
EBITDA Margin	34.3%	37.1%	18.9%	30.2%	31.8%	35.2%	18.4%	28.9%	33.2%	38.0%	21.2%	23.6%
Operating Income Margin	24.3%	27.0%	13.7%	15.5%	21.2%	24.6%	10.3%	17.0%	21.5%	21.2%	17.0%	11.3%
Net Income Margin	16.9%	21.5%	10.1%	10.5%	14.9%	17.2%	8.0%	12.0%	15.9%	16.6%	8.0%	14.9%
Cash & Debt
Total Cash	7,108	5,395	-	4,930	7,076	8,021	-	5,115	5,812	6,462	6,243	4,898
Total Debt	32,839	31,294	0	31,562	33,533	34,551	0	28,576	29,838	31,503	29,143	29,299
Net Debt / (Cash)	25,731	25,899	-	26,632	26,457	26,530	-	23,461	24,026	25,041	22,900	24,401
Cash Flows Quarterly
FCF from Operations	3,386	3,713	2,907	3,383	3,085	2,486	2,380	3,114	1,718	3,133	2,398	2,930
Cash Flows TTM
FCF from Operations TTM	13,389	13,088	11,861	11,334	11,065	9,698	10,345	10,363	10,179	9,709	9,808	8,828
Returns to Shareholders Quarterly
Dividends	10	3,347	3	1,576	17	3,033	2	1,410	22	3,047	0	1,393
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	17.3%	19.8%	-	10.3%	13.8%	15.1%	-	10.7%	13.9%	11.8%	12.6%	8.0%
Return on Invested Capital (ROIC) TTM
ROIC TTM	14.8%	13.9%	-	11.8%	11.7%	11.6%	-	12.3%	12.8%	9.6%	7.6%	1.9%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Pharmaceuticals	45,811	44,351	37,417	26,617	24,384
Total	45,811	44,351	37,417	26,617	24,384

Price Behavior

Behavior Stats
Betas Matrix

Price Behavior

Market Price	$82.11
Market Cap ($ Bil)	254.5
First Trading Date	05/17/1993
Distance from 52W High	-2.2%
	50 Days	200 Days
DMA Price	$73.97	$70.39
DMA Trend	indeterminate	up
Distance from DMA	11.0%	16.6%
	3M	1YR
Volatility	24.6%	24.9%
Downside Capture	0.15	0.32
Upside Capture	91.21	31.73
Correlation (SPY)	18.0%	28.3%
	5D	10D
Expected Return	0.2%	0.7%
Expected Excess Return	0.1%	-2.2%
Chance of Rise	46.4%	50.0%
Std Dev of Returns	0.9%	1.0%

AZN Betas & Captures as of 8/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	-0.06	0.25	0.42	0.41	0.36	0.41
Up Beta	-0.05	-0.00	0.01	0.33	0.22	0.45
Down Beta	-0.65	-0.32	0.86	0.57	0.56	0.52
Up Capture	73%	112%	68%	36%	20%	10%
Bmk +ve Days	10	22	35	71	142	415
Stock +ve Days	13	23	32	65	131	407
Down Capture	-95%	-32%	10%	42%	51%	57%
Bmk -ve Days	11	19	27	54	106	334
Stock -ve Days	8	19	31	61	117	341

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	8152025
Short Interest: Shares Quantity	6,189,751
Short Interest: % Change Since 7312025	16.2%
Average Daily Volume	4,419,391
Days-to-Cover Short Interest	1.40
Basic Shares Quantity	3,100,000,000
Short % of Basic Shares	0.2%

SEC Filings

Expand for More

Report Date	Filing
12312024	20-F 12/31/2024
3312024	6-K 3/31/2024
3312023	6-K 3/31/2023
6302022	6-K 6/30/2022
3312022	6-K 3/31/2022
3312021	6-K 3/31/2021
12312020	20-F 12/31/2020
9302020	6-K 9/30/2020
3312020	6-K 3/31/2020
6302019	6-K 6/30/2019
9302018	6-K 9/30/2018
6302018	6-K 6/30/2018
9302017	6-K 9/30/2017
6302017	6-K 6/30/2017
9302016	6-K 9/30/2016
9302015	6-K 9/30/2015

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

AstraZeneca (AZN)

Market Price (9/4/2025): $81.9 | Market Cap: $253.9 BilSector: Health Care | Industry: Pharmaceuticals

AstraZeneca (AZN)

Market Price (9/4/2025): $81.9Market Cap: $253.9 BilSector: Health CareIndustry: Pharmaceuticals

Investment Highlights

Market Valuation

Stock Price Chart

Market Cap Chart

Business Description

Price Returns Compared

Interactive Breakdown

Better Bets than AstraZeneca (AZN)

Latest Trefis Analyses

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for AstraZeneca

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (9/4/2025): $81.9 | Market Cap: $253.9 Bil
Sector: Health Care | Industry: Pharmaceuticals

Market Price (9/4/2025): $81.9
Market Cap: $253.9 Bil
Sector: Health Care
Industry: Pharmaceuticals